Search Results

You are looking at 81 - 90 of 132 items for :

  • "molecular targets" x
  • All content x
Clear All
Full access

A. Scott Paulson and Emily K. Bergsland

. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors . Endocrinol Metab Clin North Am 2010 ; 39 : 811 – 826 . 45 Capdevilla J Salazar R . Molecular targeted therapies in the treatment of

Full access

Julia R. Trosman, Christine B. Weldon, R. Kate Kelley, and Kathryn A. Phillips

NGTS panels, sequencing assays interrogating tens to hundreds of tumor genetic and molecular targets of varying clinical significance. The topics of germline genetic testing, sequencing technical and platform issues, and comparison of specific NGTS

Full access

Bin Wu and Lizheng Shi

is poor. 4 Due to the heterogeneous nature of pancreatic tumors, molecularly targeted therapies could offer physicians the opportunity to tailor a strategy to the unique properties of a patient’s individual tumor. 2 Loss-of-function mutations in

Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer . J Clin Oncol 2000 ; 18 : 2529 – 2536 . 46 Tsuruo T Naito M Tomida A . Molecular targeting therapy of cancer: drug resistance

Full access

Robin K. Kelley, Chloe Atreya, Alan P. Venook, and Phillip G. Febbo

clinical research arena to harness the immense potential, and limit the risk, of molecularly targeted therapies in oncology. References 1 Draft Guidance for Industry and Food and Drug Administration Staff - In Vitro Companion Diagnostic

Full access

Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin III, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Alyson Brown, Olivia Zalewski, Gillian Prinzing, Charles Roche, Kazunori Kanehira, Sarbajit Mukherjee, Renuka Iyer, and Christos Fountzilas

or without actionable findings. 7 This case report presents a patient who enrolled in the KYT program and received a molecularly targeted therapy for a tumor-agnostic biomarker that had only recently been approved by the FDA at the time of initiation

Full access

Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies, and Alexander J. Lazar

affordability of high-throughput sequencing platforms have facilitated the identification of relevant molecular targets. 33 , 36 – 41 BRAF and MEK inhibitors for melanoma with BRAF p.V600E, EGFR inhibitors for RAS wild-type colorectal cancer, KIT inhibitors

Full access

Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang, and Rui-Hua Xu

Cancer 2015 ; 51 : 1405 – 1414 . 10.1016/j.ejca.2015.03.015 26. Okuno M , Hatano E , Nishino H , . Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable

Full access

Aatur D. Singhi, Siraj M. Ali, Jill Lacy, Andrew Hendifar, Khanh Nguyen, Jamie Koo, Jon H. Chung, Joel Greenbowe, Jeffrey S. Ross, Marina N. Nikiforova, Herbert J. Zeh, Inderpal S. Sarkaria, Anil Dasyam, and Nathan Bahary

susceptibility to immune checkpoint inhibitors. 7 However, these “actionable” genetic alterations are relatively uncommon and, consequently, there is an urgent need to identify additional molecular targets. In recent years, chromosomal rearrangements involving

Full access

Kamya Sankar and Brady L. Stein

provided molecular targets for drug development in both PV and ET. The primary goals of treatment for MPNs are to reduce the risk of thrombosis and alleviate systemic symptom burden (eg, fatigue, pruritus, microvascular symptoms, symptomatic splenomegaly